“…Imatinib mesylate (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ, USA) is a selective inhibitor of the bcr-abl, c-kit, and platelet-derived growth factor receptor tryrosine kinases and is a promising new targeted therapy for patients with chronic myelogenous leukaemia and gastrointestinal stromal tumours. [1][2][3][4][5] Imatinib mesylate is generally well tolerated, with frequent but mild side effects. Reported side effects include myalgia, fatigue, nausea, dyspepsia, diarrhoea, oedema, and liver-function abnormalities.…”